Research and Development
CSL is a global specialty biopharmaceutical company that aims to identify, develop and commercialise important, new, biotherapeutic products that help to save lives by preventing or treating serious medical conditions. CSL are committed to significantly investing in its future R&D portfolio and capabilities in the areas of immunoglobulins, specialty products, haemophilia products and breakthrough medicines.
CSL's strong commitment to funding research and development of protein based medicines for unmet medical needs underpins its continued growth.
CSL operates as one integrated global research and development organisation. CSL assembles co-ordinated global project teams drawing together staff from different countries depending on their expertise. These teams rely on a project management framework that facilitates collaboration across national and cultural boundaries.
To complement in-house expertise CSL also draws on strategic partnerships with academic institutions and other organisations globally. These collaborative partnerships support a range of effective research programs, including both basic and applied research in plasma derived and recombinant protein based product development.
R&D Briefing December 2015 (4Mb)|
R&D Briefing December 2014 (7.6Mb)
R&D Briefing December 2013 (7Mb)
R&D Briefing December 2012 (4Mb)
R&D Briefing December 2011 (4.8Mb)
R&D Briefing December 2010 (3.6Mb)
R&D Briefing December 2009 (2.34Mb)
R&D Briefing Dec 2008
R&D Briefing Dec 2007